Hepatitis C: Update Bulletin
[Published by FirstWord Pharma]
Published by FirstWord Pharma: 01 Feb 2016 | 307 | In Stock
Gain new KOL insights on the latest events that have the potential to shape the hepatitis C virus (HCV) treatment landscape. Topics covered include KOL insights on how Merck & Co.’s Zepatier (elbasvir and grazoprevir) is likely to be used as a treatment for HCV, and if the additional testing requirements could slow down adoption; what KOLs think of AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with a dasabuvir tablet) now being approved without the need for ribavirin; reaction to data from the ASTRAL trial for Gilead’s sofosbuvir with velpatasvir, and if the data could provide Gilead with an edge in the GT3 HCV treatment space; thoughts on the potential impact of adding GS9857 to Gilead’s sofosbuvir and velpatasvir, and if a short treatment regimen is attractive to KOLs.
Key Questions Answered in this Update Bulletin:
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Table of Contents
for Hepatitis C: Update Bulletin [February 2016] [Published by FirstWord Pharma]
|Title||Date Published||Price from||More Details|
| Global Hepatitis Partnering 2010 to 2016|
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
|01 Oct 2016 by Current Partnering||USD $1,271 (normally
| Alcoholic Hepatitis Global Clinical Trials Review, H2, 2015|
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report...
|16 Dec 2015 by Global Data||USD $2,125 (normally
| Hepatitis C: KOL Insight|
IntroductionThe Hepatitis C (HCV) market will be driven by meeting the needs of under-served patient...
|01 Sep 2015 by FirstWord Pharma||USD $6,715 (normally
| Physician Views: The hepatitis C pricing war - what impact on prescribers?|
Scope In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Vi...
|29 Jan 2015 by FirstWord Pharma||USD $591 (normally
| Payer Insights: Hepatitis C|
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
|26 Sep 2014 by FirstWord Pharma||USD $6,715 (normally
| Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?|
Scope Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tr...
|08 Jul 2014 by FirstWord Pharma||USD $591 (normally
| Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014?|
Scope With this year's meeting of the International Liver Congress (EASL) just over a week away (Apr...
|01 Apr 2014 by FirstWord Pharma||USD $591 (normally
| Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook|
IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
|01 Dec 2013 by FirstWord Pharma||USD $4,246 (normally
| Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?|
Scope Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, inter...
|01 Nov 2013 by FirstWord Pharma||USD $591 (normally
| Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?|
ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
|01 Oct 2013 by FirstWord Pharma||USD $591 (normally
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.